Lexeo’s Approach To Gene Therapy For Common Conditions

CEO Expects First Commercial Launch As Early As 2026

 
• By Chloe Kent

Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.

Hand inserting a sequence of DNA

Rising Leaders Home

Something that sets Lexeo Therapeutics apart from a lot of other gene therapy firms, as highlighted by CEO R. Nolan...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rising Leaders

More from Leadership